MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, using T315I mutation harboring sublines of well-characterized CML lines we proved that inhibition of BCR-ABL1 kinase activity is essential, while the off-target effects of TKIs do not play a key role in the synergistic proapoptotic interaction between MCL1 inhibition and TKI therapy in CML cells.